These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11426332

  • 1. A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination.
    Dupont F, Karim A, Dumon JC, Mine N, Avalosse B.
    Gene Ther; 2001 Jun; 8(12):921-9. PubMed ID: 11426332
    [Abstract] [Full Text] [Related]

  • 2. Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmids.
    Clément N, Velu T, Brandenburger A.
    Cancer Gene Ther; 2002 Sep; 9(9):762-70. PubMed ID: 12189526
    [Abstract] [Full Text] [Related]

  • 3. A novel packaging system for the generation of helper-free oncolytic MVM vector stocks.
    Brandenburger A, Russell S.
    Gene Ther; 1996 Oct; 3(10):927-31. PubMed ID: 8908507
    [Abstract] [Full Text] [Related]

  • 4. Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus.
    Brandenburger A, Velu T.
    J Gene Med; 2004 Feb; 6 Suppl 1():S203-11. PubMed ID: 14978763
    [Abstract] [Full Text] [Related]

  • 5. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
    Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO.
    J Gene Med; 1999 Feb; 1(3):176-85. PubMed ID: 10738566
    [Abstract] [Full Text] [Related]

  • 6. Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences.
    Clément N, Avalosse B, El Bakkouri K, Velu T, Brandenburger A.
    J Virol; 2001 Feb; 75(3):1284-93. PubMed ID: 11152501
    [Abstract] [Full Text] [Related]

  • 7. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
    Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA.
    Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
    [Abstract] [Full Text] [Related]

  • 8. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector.
    Dupont F, Avalosse B, Karim A, Mine N, Bosseler M, Maron A, Van den Broeke AV, Ghanem GE, Burny A, Zeicher M.
    Gene Ther; 2000 May; 7(9):790-6. PubMed ID: 10822306
    [Abstract] [Full Text] [Related]

  • 9. Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.
    Hettich E, Janz A, Zeidler R, Pich D, Hellebrand E, Weissflog B, Moosmann A, Hammerschmidt W.
    Gene Ther; 2006 May; 13(10):844-56. PubMed ID: 16421600
    [Abstract] [Full Text] [Related]

  • 10. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
    Yu SS, Han E, Hong Y, Lee JT, Kim S, Kim S.
    Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 12. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
    Barjot C, Hartigan-O'Connor D, Salvatori G, Scott JM, Chamberlain JS.
    J Gene Med; 2002 May; 4(5):480-9. PubMed ID: 12221641
    [Abstract] [Full Text] [Related]

  • 13. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells.
    Wrzesinski C, Tesfay L, Salomé N, Jauniaux JC, Rommelaere J, Cornelis J, Dinsart C.
    J Virol; 2003 Mar; 77(6):3851-8. PubMed ID: 12610161
    [Abstract] [Full Text] [Related]

  • 14. Humoral immune responses against minute virus of mice vectors.
    Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ.
    J Gene Med; 2006 Sep; 8(9):1141-50. PubMed ID: 16800041
    [Abstract] [Full Text] [Related]

  • 15. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Zhang J, Frolov I, Russell SJ.
    J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
    [Abstract] [Full Text] [Related]

  • 16. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW, Morris JC, Ehninger G, Ramsey WJ.
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [Abstract] [Full Text] [Related]

  • 17. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously.
    Qian Q, Sham J, Che X, Xu J, Xue H, Cui Z, Zhu B, Wu M.
    Chin Med J (Engl); 2002 Aug; 115(8):1213-7. PubMed ID: 12215295
    [Abstract] [Full Text] [Related]

  • 18. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
    Finger C, Sun Y, Sanz L, Alvarez-Vallina L, Buchholz CJ, Cichutek K.
    Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
    [Abstract] [Full Text] [Related]

  • 19. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.
    Cancer Res; 2001 Dec 15; 61(24):8743-50. PubMed ID: 11751394
    [Abstract] [Full Text] [Related]

  • 20. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, Dropulic B.
    J Gene Med; 2005 Jun 15; 7(6):818-34. PubMed ID: 15693055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.